Abstract: The present disclosure relates to molecules capable of binding to both CD20 and PD1, as well as pharmaceutical compositions comprising such molecules and methods of use thereof.

Abstract: A virtual reality interaction method and apparatus, a device and a storage medium are provided. The method includes: displaying, on a terminal, a real-time captured real-world scene image; wherein the real-world scene image includes a virtual model; extending a scene edge of the virtual model towards a screen edge of the terminal; switching a scene image displayed on the terminal from the real-world scene to a virtual scene in response to detecting that a viewpoint of the terminal crosses a plane where the scene edge of the virtual model located,; and obtaining an interactive instruction for the virtual scene and displaying an interactive effect corresponding to the interactive instruction.

Abstract: We describe an antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) sequence and a light chain variable region (VL) sequence of a clone selected from: 5C4, 4H1, 1D2, 1C4, 2B5, 1F1, 1H1, 4A5, 1D8, 1D3, 2F1, 3C6, 3D12, 3A9, 1F4, 1H10, 3C12, 4G11, 4A12, 1A12, 3G12, 4F9, 4G4 and 1E1 which is capable of specifically binding to glypican-3 (GPC-3) (GenBank Accession Number: NP_004475.1), or a sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto.

Abstract: A light emitting device includes: a first electrode; a second electrode disposed opposite to the first electrode; and multiple emission layers stacked between the first electrode and the second electrode. The emission layers include at least one first emission layer and at least one second emission layer. The first emission layer includes a first luminescent material, and is configured to emit a first light when driven by a current or voltage; the second emission layer includes a second luminescent material, and is configured to emit a second light when driven by the current or voltage; a luminous efficiency of the first luminescent material is greater than that of the second luminescent material; and a luminance conversion rate when performing optical excitation on color conversion materials by the first light is smaller than that when performing optical excitation on the color conversion materials by the second light.

Abstract: The invention relates to recombinant mutated angiotensin converting enzyme 2 (ACE2) comprising one or more amino acid substitutions at amino acid positions T27, F28, K31, H34, Y41 and Q42 which have improved binding affinity to SARS-CoV-1 and/or SARS-CoV-2. It also relates to combinatorial mutant ACE2 comprising T27Y/K31 H/H34A, T27YZ K31 H/H134V and T27Y/K31 Y/H134V and the use of said mutant ACE2 for treating and preventing coronavirus infection.

Abstract: A material with a hole injection function and/or a hole transport function includes a host material and a crystallisation inhibitor doped in the host material. The crystallisation inhibitor is capable of inhibiting crystallisation of the host material during evaporation, and the crystallisation inhibitor has a hole injection function and/or a hole transport function.

Abstract: We describe an antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) sequence and a light chain variable region (VL) sequence of a clone selected from: 5C4, 4H1, 1D2, 1C4, 2B5, 1F1, 1H1, 4A5, 1D8, 1D3, 2F1, 3C6, 3D12, 3A9, 1F4, 1H10, 3C12, 4G11, 4A12, 1A12, 3G12, 4F9, 4G4 and 1E1 which is capable of specifically binding to glypican-3 (GPC-3) (GenBank Accession Number: NP_004475.1), or a sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto.

Abstract: Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.

Abstract: Various embodiments support or provide for an extensible electronic claim verification system that offers extensible support for electronic verification by one or more external electronic claim verification services that are external to the extensible electronic claim verification system. For some embodiments, the extensible claim verification system is readily configurable (e.g., by a user) to add or remove access to one or more external claim verification services available for use through the extensible electronic claim verification system by a client device. Some embodiments implement the extensible support by using a unified protocol for interfacing with different external claim verification services. By use of the unified protocol, various embodiments enable an external claim verification service to plug into an extensible claim verification system, thereby permitting a user to extend support of the extensible claim verification system to different types of external claim verification services.

Abstract: A virtual reality interaction method and apparatus, a device and a storage medium are provided. The method includes: displaying, on a terminal, a real-time captured real-world scene image; wherein the real-world scene image includes a virtual model; extending a scene edge of the virtual model towards a screen edge of the terminal; switching a scene image displayed on the terminal from the real-world scene to a virtual scene in response to detecting that a viewpoint of the terminal crosses a plane where the scene edge of the virtual model located,; and obtaining an interactive instruction for the virtual scene and displaying an interactive effect corresponding to the interactive instruction.

Abstract: The present disclosure relates to molecules capable of binding to both CD20 and PD1, as well as pharmaceutical compositions comprising such molecules and methods of use thereof.

Abstract: An electroluminescent device, a method for manufacturing the electroluminescent device, a display panel and a display device are provided in the embodiments of the present application. The electroluminescent device includes an anode layer, a first hole injection layer and a hole transport layer. The first hole injection layer is located between the anode layer and the hole transport layer; the first hole injection layer includes at least two secondary hole injection layers, and an equivalent resistance value of the at least two secondary hole injection layers is greater than a first threshold value.

Abstract: The present disclosure relates to molecules capable of binding to both CD20 and PD1, as well as nucleic acids encoding such molecules, pharmaceutical compositions comprising such molecules, and methods of use thereof. In certain aspects, disclosed are CD20-PD1 binding molecules comprising at least one CD20 targeting moiety and at least one PD1 agonist moiety, where in certain aspects the PD1 agonist moiety is a PDL1 or PDL2 ectodomain or a PD1 binding portion thereof.

Abstract: A low-carbon, green and efficient preparation method for soybean oil body-curcumin emulsion includes following steps: soybeans are mixed with NaHCO3 solution at a ratio of 1:7, soaked in the NaHCO3 solution at 4° C. for 20 h and blended with a blender for 6 min to obtain soybean slurry, pH of the soybean slurry is adjusted to 11.0, then the soybean slurry is stirred for 2 h at 50° C. in a water bath to obtain stirred slurry, the stirred slurry is filtered to obtain a suspension, and the suspension is centrifuged to obtain a soybean oil body; curcumin is dissolved with 0.2 M NaOH and then mixed with the soybean oil body to obtain a mixed emulsion, and pH of the mixed emulsion is adjusted to 6.5-8.0 and then the mixed emulsion is stirred for 30 min in dark to obtain the soybean oil body-curcumin emulsion.

Abstract: A light emitting device includes: a first electrode; a second electrode disposed opposite to the first electrode; and multiple emission layers stacked between the first electrode and the second electrode. The emission layers include at least one first emission layer and at least one second emission layer. The first emission layer includes a first luminescent material, and is configured to emit a first light when driven by a current or voltage; the second emission layer includes a second luminescent material, and is configured to emit a second light when driven by the current or voltage; a luminous efficiency of the first luminescent material is greater than that of the second luminescent material; and a luminance conversion rate when performing optical excitation on color conversion materials by the first light is smaller than that when performing optical excitation on the color conversion materials by the second light.

Abstract: A light emitting substrate includes: a first base substrate, a plurality of light emitting devices located on the first base substrate, wherein the light emitting devices include a first light emitting device, a second light emitting device and a third light emitting device, each of the light emitting devices includes a first electrode layer, a light emitting functional layer and a second electrode layer which are stacked, the light emitting functional layer includes an emitting layer including a first emitting layer in the first light emitting device, a second emitting layer in the second light emitting device and a third emitting layer in the third light emitting device; the material of the first emitting layer is different from the material of the second emitting layer, and the material of the first emitting layer is different from the material of the third emitting layer.

Abstract: Provided is a high throughput screening method for identifying cell fusion or syncytium formation potential. In particular, the cell fusion or syncytium formation potential of a viral spike protein. Also provided is a method for identifying a cellular factor that promotes spike protein-induced syncytium formation. Also provided is a method of inhibiting or suppressing syncytium formation induced by a viral spike protein.

Abstract: Provided are an image fusion method and apparatus, an electronic device, and a storage medium. The method includes the following steps: A shooting operation acting on a first page of a target shooting activity is received, where the first page is an H5 page; in response to the shooting operation, a camera is called through system shooting software to collect an original image; a fusion operation for the original image is received; and in response to the fusion operation, the original image is fused with a first target effect, a static target image that includes a static image obtained by fusing the original image with the first target effect and the first description information related to the static image is generated, and the static target image is displayed on a second page, where the second page is an H5 page.

Abstract: Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.

Abstract: A material with a hole injection function and/or a hole transport function includes a host material and a crystallisation inhibitor doped in the host material. The crystallisation inhibitor is capable of inhibiting crystallisation of the host material during evaporation, and the crystallisation inhibitor has a hole injection function and/or a hole transport function.